AvgoustaIoannou Mission BioUnited Kingdom

AvgoustaIoannou
Biography - A career across Research & Development at Illumina, moving to Stilla Technologies, and Bio-Rad. Now supporting scientists across the UK and EMEA at Mission Bio as Senior Field Application Scientist with cutting-edge single-cell multi-omics solutions.

Wednesday 10 June 2026

Time Session
08:30
09:15
TP53 mutations are common in AML, often as “multi-hit” types linked to complex karyotypes. Using single-cell DNA sequencing and phenotypic analysis, we examined the zygosity and clonal architecture of TP53m AML. Among eight patients, “multi-hit” TP53 anomalies appeared in blast cells but not in mature lymphoid populations. Minor TP53m heterozygous clones persisted in mature cells and at remission, with dominant “multi-hit” clones resurfacing at relapse. The combined scDNAseq and CITEseq approach highlights distinct mutation patterns, aiding therapy guidance by distinguishing pathological multi-hit mutations from clonal haematopoiesis at remission.
JenniferStobbs Industry Moderator/ Chair Mission BioUnited States
Room F6+7+8